Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study)
Robert E. Shaddy(University of Southern California), Fabian Chen(Brighton Hospital), Paul F. Kantor(American College of Cardiology), Damien Bonnet(World Rugby), Lazaros Kochilas(Emory Healthcare), Michael Burch(Great Ormond Street Hospital), Christopher Bush, Nancy Halnon(University of California, Los Angeles), Charles E. Canter(St. Louis Children's Hospital), Ziqiang Zhao(Novartis (China)), Joseph W. Rossano(Children's Hospital of Philadelphia)
Cited by 98
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Changes in health in England, with analysis by English regions and areas of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|361
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|The Lancet Haematology|2019|329
Prevalence, Morbidity, and Mortality of Heart Failure–Related Hospitalizations in Children in the United States: A Population-Based Study
|Journal of Cardiac Failure|2012|301
D-Transposition of the Great Arteries
|Journal of the American College of Cardiology|2014|289